sellNotable cluster of 4
Cedric Francois sold $6.4M of APLS
Chief Executive Officer at Apellis Pharmaceuticals, Inc.. 225,000 shares at an average of $28.23, traded Aug 27, 2025, filed Aug 29, 2025.
Warning score
75Value
$6.4M
225,000 shares
Holdings after
307,946
-42% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$6.4M at market
- +10Share of holdings soldSold 42% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-192797, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 27, 2025 | SOpen-market sale Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) | -175,037 | $28.19 | $4.9M | 357,909 | Aug 29, 2025 |
| Aug 28, 2025 | SOpen-market sale Common Stockindirect: Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) | -49,963 | $28.39 | $1.4M | 307,946 | Aug 29, 2025 |
Related signals
Other insiders at Apellis Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | APLSsell Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $8,153 368 shares | -0% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $170k 7,832 shares | -8% | |
| 49Moderate | Apellis Pharmaceuticals, Inc. | Timothy Eugene Sullivan Chief Financial Officer | $224k 10,287 shares | -10% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Nur Nicholson Chief Technical Officer | $168k 7,725 shares | -10% | |
| 59Moderate | Apellis Pharmaceuticals, Inc. | Cedric Francois Chief Executive Officer | $592k 27,192 shares | -9% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Pascal Deschatelets Chief Scientific Officer | $129k 5,928 shares | -1% | |
| 38Weak | Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $73k 3,371 shares | -4% | |
| 36Weak | Apellis Pharmaceuticals, Inc. | James George Chopas VP/Chief Accounting Officer | $45k 2,064 shares | -4% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | Caroline Baumal Chief Medical Officer | $61k 2,797 shares | -3% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $49k 2,475 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.